Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s
Sherwood News • • business
Key Points:
- Strive Specialties, a major compounding pharmacy, has sued Eli Lilly and Novo Nordisk, accusing them of restricting telehealth companies from working with compounders to limit access to GLP-1 weight-loss drugs.
- Telehealth companies like Ro, Weight Watchers, and LifeMD have exclusive partnerships with Lilly and Novo to distribute branded weight-loss medications, barring them from collaborating with compounders who offer personalized, often cheaper versions.
- Strive argues these exclusive agreements reduce prescriber choice and patient access, citing Novo’s termination of its partnership with Hims & Hers after it continued selling compounded versions of Wegovy.
- Lilly previously sued Strive for alleged false marketing, but the case was dismissed in Delaware and refile
 { path { fill: %23EEEFE9 } })